Preclinical Development of EDIT-401, a Durable In Vivo CRISPR Gene Editing Therapy That Upregulates LDLR Protein to Lower LDL-C

Sep

9

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

Sep

8

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Sep

1

Editas Medicine to Participate in Upcoming Investor Conferences